Yazar "Aktan, M." seçeneğine göre listele
Listeleniyor 1 - 13 / 13
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Adjuvant chemotherapy after preoperative chemoradiotherapy for rectal cancer(Oxford Univ Press, 2015) Kanyilmaz, G.; Koc, M.; Aktan, M.Adjuvant chemotherapy has been very questionable recently. In this regards, the study which was designed by A.J. Breugom and colleagues :'Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Clorectal Cancer Group (DCCG) randomized phase III trial' caught our attention. We read this trial with very interest. However from our point our view there are some limitations of this study and we want to make some suggestion and some criticism for study.Öğe CLINICAL MANAGEMENT AND QUALITY OF LIFE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA UNDERGOING LIPID-APHERESIS IN TURKEY: FIRST RESULTS OF A NATION-WIDE SURVEY (A-HIT REGISTRY)(Elsevier Ireland Ltd, 2016) Kayikcioglu, M.; Tokgozoglu, L.; Pirildar, S.; Yilmaz, M.; Kaynar, L.; Aktan, M.; Durmus, R.[Abstract Not Availabe]Öğe Comparison of the Effects of Melatonin, Tymoquinone and Amifostine on Peripheral Blood Cells During Total Body Irradiation in Rats(Elsevier Science Inc, 2015) Koc, M., Sr.; Cetinkaya, C. D.; Aktan, M.; Gurbilek, M.; Tezcan, Y.; Adli, M.[Abstract Not Availabe]Öğe The Effect of Hormonotherapy on the Development of Lung Fibrosis after Radiotherapy in Breast Cancer Patients(Elsevier Science Inc, 2020) Yavuz, B. Benli; Poyraz, N.; Kanyilmaz, G.; Aktan, M.; Tuncez, I.; Koc, M., Sr.[Abstract Not Availabe]Öğe The Effects of ORAL Glutamine Supplementation on Clinical and Survival Outcomes of Non-Small Cell Cancer Patients Treated With Chemoradiation Therapy(Elsevier Science Inc, 2015) Kanyilmaz, G.; Koc, M., Sr.; Aktan, M.; Temiz, S. A.; Adli, M.[Abstract Not Availabe]Öğe Machine Learning Based Prediction of Distant Metastasis in Rectal Cancer Patients with Complete Response following Neoadjuvant Chemoradiotherapy(Elsevier Science Inc, 2023) Ozden, G.; Adli, M.; Aktan, M.; Gunes, S.; Acikgoz, S. Gokhan; Alkis, H.; Tezcan, Y.[Abstract Not Availabe]Öğe A nation-wide survey of patients with homozygous familial hypercholesterolemia undergoing lipoprotein-apheresis in Turkey (A-HIT Registry)(Oxford Univ Press, 2016) Kayikcioglu, M.; Tokgozoglu, L.; Yilmaz, N.; Kaynar, L. G.; Aktan, M.; Durmus, R.; Temizhan, A.[Abstract Not Availabe]Öğe Outcome and toxicity of reirradiation for locally recurrent small cell lung cancer: An international multicenter study(Elsevier Science Inc, 2021) Kaesmann, L.; Janssen, S.; Baschnagel, A. M.; Kruser, T. J.; Harada, H.; Aktan, M.; Rades, D.[Abstract Not Availabe]Öğe Prognostic importance of 18F-fiuorodeoxyglucose uptake by positron emission tomography for stage III non-small cell lung cancer treated with definitive chemoradiotherapy(Elsevier Espana Slu, 2020) Kanyilmaz, G.; Yavuz, B. Benli; Aktan, M.; Sahin, O.Objectives: Survival heterogeneity exists among patients with non-small cell lung cancer (NSCLC), even within the same stage. We aimed to evaluate the prognostic role of pre-treatment maximum standardized uptake value (SUVmax) in patients treated with definitive concurrent chemoradiotherapy for stage III NSCLC. Materials and methods: Between 2010 and 2017, 103 patients with stage III NSCLC who underwent F-18-FDG PET/CT at the time of diagnosis were included in the study. Results: Higher tumor stages were correlated with higher pre-treatment SUVmax of lymph nodes (LNs) (p = 0.005) but were not correlated with higher SUVmax of primary tumor (p = 0.2). The median SUV max of LNs was 2.84, 8.06, and 11.11 in stage IIIa, IIIb and IIIc, respectively. Higher nodal stage was also correlated with higher SUVmax of LNs (p - 0.01). According to ROC analysis, there was no significant cut-off value of SUVmax observed for primary tumor, therefore continuous variables were used for survival analyses. The best SUVmax cut-off was 3.5 for the LNs, therefore the SUVmax of LNs was evaluated as both a dichotomous and a continuous variable. Pre-treatment SUVmax of primary tumor did not predict survival outcomes but both the continuous and dichotomous variables of SUV(max )of LNs predicted recurrence free survival and overall survival. Nodal stage (N0-2 vs. N3) and AJCC stage (IIIa vs IIIb vs. IIIc) were the other prognostic factors. Conclusions: Pre-treatment SUVmax of LNs had prognostic value in patients treated with definitive concurrent chemoradiotherapy for stage III NSCLC. In future trials, pre-treatment SUVmax of the LNs would serve as a guide for patients who might benefit from more aggressive treatments. (C) 2019 Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Medicina Nuclear e lmagen Molecular.Öğe Prognostic Importance of Ki-67 Labeling Index in WHO Grade II Glial Tumors(Elsevier Science Inc, 2017) Kanyilmaz, G.; Onder, H.; Aktan, M.; Sr, M. Koc; Bora, H.; Eray, K.; Yirmibesoglu, E.[Abstract Not Availabe]Öğe Prognostic Importance of PTEN, EGFR, HER 2, and IGF-1R in Gastric Cancer Patients Treated With Postoperative Chemoradiation Therapy(Elsevier Science Inc, 2014) Yavuz, B. Benli; Koc, M.; Kozacioglu, S.; Aktan, M.; Tezcan, Y.; Adli, M.[Abstract Not Availabe]Öğe Protective effects of growth hormone on bacterial translocation and intestinal damage in rats with partial intestinal obstruction(Comenius Univ, 2014) Kaymakci, A.; Guven, S.; Ciftci, I; Akillioglu, I; Aktan, M.; Eker, H. H.; Sutcu, A.Objective: One of the reasons of bacterial translocation (BT) is the complete or partial intestinal obstructions (PIO) of the gastrointestinal system. In this study, we aimed to investigate the effects of recombinant human Growth Hormone (rhGH) on BT in rats with partial intestinal obstruction (PIO). Material and methods: The rats were randomly divided into the 4 groups: Group I: Sham-operated (SO) (n = 12), Group II control PIO (n = 12), Group III: PIO with rhGH treatment for 5 days (n = 12), Group IV: PIO with rhGH treatment 5 days before PIO and 5 days after PIO (a total of 10 days) (n = 12). In the groups III and IV, the effects of 5 and 10 days administered rhGH were examined. Results: The level of serum and of intestinal fluid IgA was significantly higher in the Group IV compared to the Group I, Group II and Group III. In the Group IV, the number of small intestinal goblet and colonic goblet cells, and the lengths of intestinal mucosal villi and crypt depths were statistically significantly higher than in Groups II and III. The rate of bacterial translocation was higher in the Group II: 100 % in MLNs, 41.6 % in blood culture and 50.8 % in the liver cultures, it was significantly higher compared to the other groups (p < 0.01). Conclusions: The study results demonstrated that administration of rhGH to the rats with PIO for at least 10 days decreased bacterial translocation (Fig. 3, Ref. 25). Text in PDF www.elis.sk.Öğe Thoracic Re-irradiation in small cell Lung Cancer (SCLC) - an International Multicenter Study(Springer Heidelberg, 2020) Kaesmann, L.; Janssen, S.; Baschnagel, A.; Kruser, T.; Harada, H.; Aktan, M.; Rades, D.[Abstract Not Availabe]
